Drug Profile
Fezagepras - Liminal BioSciences
Alternative Names: PBI 4050; Setogepram - Liminal BioSciencesLatest Information Update: 04 Aug 2022
Price :
$50
*
At a glance
- Originator ProMetic Life Sciences
- Developer Liminal BioSciences
- Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Hepatoprotectants; Phenylacetates; Skin disorder therapies; Small molecules
- Mechanism of Action Ammonia scavengers; AMP activated protein kinase modulators; Autophagy stimulants; Cell differentiation modulators; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; FFAR1 protein stimulants; GPR84 protein antagonists; Immunomodulators; Inflammation mediator inhibitors; MTOR protein inhibitors; MTOR protein modulators; PPAR alpha modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute lung injury; Alstrom's Syndrome; Anaemia; Cystic fibrosis; Diabetic nephropathies; Haematological disorders; Hyperammonaemia; Hypertriglyceridaemia; Idiopathic pulmonary fibrosis; Liver disorders; Metabolic syndrome; Neutropenia; Non-alcoholic fatty liver disease; Pulmonary hypertension; Renal fibrosis; Scleroderma; Type 2 diabetes mellitus
Most Recent Events
- 29 Jul 2022 Liminal BioSciences terminates a phase Ia trial in Hyperammonaemia (In volunteers) in United Kingdom, due to discontinuation of drug development by company (PO) (NCT05349435)
- 29 Jul 2022 Discontinued - Phase-I for Hyperammonaemia (In the elderly, In volunteers, In adults) in United Kingdom (PO)
- 21 Jul 2022 Liminal Biosciences terminates a phase II/III trial in Idiopathic pulmonary fibrosis prior to enrolment due to discontinuation of drug development by company (PO)